Stock Analysis

There May Be Some Bright Spots In Stryker's (NYSE:SYK) Earnings

NYSE:SYK
Source: Shutterstock

The market for Stryker Corporation's (NYSE:SYK) shares didn't move much after it posted weak earnings recently. Our analysis suggests that while the profits are soft, the foundations of the business are strong.

See our latest analysis for Stryker

earnings-and-revenue-history
NYSE:SYK Earnings and Revenue History February 5th 2025

The Impact Of Unusual Items On Profit

To properly understand Stryker's profit results, we need to consider the US$1.3b expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Stryker doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Stryker's Profit Performance

Unusual items (expenses) detracted from Stryker's earnings over the last year, but we might see an improvement next year. Because of this, we think Stryker's earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share have grown at 49% per year over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example - Stryker has 2 warning signs we think you should be aware of.

Today we've zoomed in on a single data point to better understand the nature of Stryker's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:SYK

Stryker

Operates as a medical technology company.

Flawless balance sheet average dividend payer.

Community Narratives

Priced for AI perfection - cracks are emerging
Fair Value US$90.15|31.613999999999997% overvalued
ChadWisperer
ChadWisperer
Community Contributor
NVDA Market Outlook
Fair Value US$341.12|65.218% undervalued
NateF
NateF
Community Contributor
Karoon Energy (ASX:KAR) - Buy Baby Buy 🚀
Fair Value AU$5.91|72.843% undervalued
StockMan
StockMan
Community Contributor